Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Analysis

Changing epidemiology and emerging risk groups for pertussis

Eleni Galanis, Arlene S. King, Paul Varughese and Scott Alan Halperin
CMAJ February 14, 2006 174 (4) 451-452; DOI: https://doi.org/10.1503/cmaj.050379
Eleni Galanis
*at the time of writing: Canadian Field Epidemiology Program, Public Health Agency of Canada, Ottawa, Ont., currently: B.C. Centre for Disease Control, Vancouver, B.C.; †Immunization and Respiratory Infections Division, Public Health Agency of Canada, Ottawa, Ont.; ‡(on behalf of the IMPACT investigators) IWK Health Centre and Dalhousie University, Halifax, N.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arlene S. King
*at the time of writing: Canadian Field Epidemiology Program, Public Health Agency of Canada, Ottawa, Ont., currently: B.C. Centre for Disease Control, Vancouver, B.C.; †Immunization and Respiratory Infections Division, Public Health Agency of Canada, Ottawa, Ont.; ‡(on behalf of the IMPACT investigators) IWK Health Centre and Dalhousie University, Halifax, N.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Varughese
*at the time of writing: Canadian Field Epidemiology Program, Public Health Agency of Canada, Ottawa, Ont., currently: B.C. Centre for Disease Control, Vancouver, B.C.; †Immunization and Respiratory Infections Division, Public Health Agency of Canada, Ottawa, Ont.; ‡(on behalf of the IMPACT investigators) IWK Health Centre and Dalhousie University, Halifax, N.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Scott Alan Halperin
*at the time of writing: Canadian Field Epidemiology Program, Public Health Agency of Canada, Ottawa, Ont., currently: B.C. Centre for Disease Control, Vancouver, B.C.; †Immunization and Respiratory Infections Division, Public Health Agency of Canada, Ottawa, Ont.; ‡(on behalf of the IMPACT investigators) IWK Health Centre and Dalhousie University, Halifax, N.S.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Pertussis remains one of the least well-controlled vaccine-preventable diseases for which routine vaccination exists. Although most often a persistent but relatively benign respiratory illness, pertussis can result in serious consequences, such as pneumonia, seizures, encephalopathy and death, especially among infants.

Pertussis whole-cell vaccine was introduced in Canada in 1943, and the reported incidence of the disease dropped by 90% in the ensuing 40 years. However, it increased again in the early 1990s and has remained high since then (Fig. 1). A 5-component acellular pertussis vaccine became available in 1997. This vaccine has a lower incidence of adverse reactions and a higher efficacy (3 doses prevented 85% of cases over a 2-year period)1 than the whole-cell vaccine used in Canada (efficacy of less than 60% for 5 doses).2 Pertussis vaccine coverage rates remained stable in Canada between 1985 and 2002: during that period 80%–91% of children received 3 doses by age 2.3

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Fig. 1: Pertussis incidence rate, Canada, 1924–2002. The incidence dropped after a vaccine was introduced in 1943 and reached an all-time low of 4.3 per 100 000 in 1988. Since then, the incidence has increased again, remaining between 9.5 and 35 per 100 000 per year between 1991 and 2002, with an average of 5720 cases reported each year.

Pertussis is most easily diagnosed in young children because they present with whooping cough, which is characterized by paroxysmal coughing followed by an audible inspiratory whoop and, occasionally, vomiting. Infants, immunized children, adolescents and adults do not usually exhibit whooping cough. Infants often present with cough and apneic episodes. They can be severely ill and may require admission to hospital. Adolescents and adults may be asymptomatic or present with a cough lasting several weeks. Although pertussis is a reportable disease, recognition of the illness by physicians is hampered by the nonspecific symptoms in adolescents and adults.

Interpreting changes in pertussis incidence rates is challenging. An increased awareness among physicians of the clinical presentation of the disease in adolescents and adults may explain some of the increase in reported cases in these age groups in the 1990s (Fig. 2). Pertussis can be diagnosed by culture and polymerase chain reaction testing of a nasopharyngeal swab or aspirate. Polymerase chain reaction testing became widely available in Canadian hospitals and laboratories in the mid-to late 1990s, which increased the capacity to diagnose the disease.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Fig. 2: Age-specific pertussis incidence rates, Canada, 1988–2002. The highest incidence has remained among infants. The incidence has been dropping among children younger than 10 years of age since 1998, but in the 1990s it increased among those 10 years and older. Since 2000, children 10–14 years of age have had the second highest incidence after that observed among infants. The proportion of cases among adults (> 19 years) increased from 6% of all cases in 1988 to 18% of all cases in 2002.

However, most of the recent increase in the rate of pertussis is due to waning natural and vaccine-induced immunity, which occurs 6–12 years after the last episode of illness or booster dose. The highest increase in rates of the disease in the 1990s was among adolescents and adults. During this decade, excluding infants, the highest incidence was observed in a cohort of children born between 1988 and 1992 (Fig. 3) who received a low-efficacy whole-cell vaccine and experienced early waning immunity.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Fig. 3: Pertussis incidence by age among children in 4 provinces in 1995, 1998 and 2000. During the 1990s, excluding infants, the highest incidence was observed among children born between the late 1980s to early 1990s: in 1995, the highest incidence was observed among children 3 years of age, in 1998 among those 6 years of age and in 2000 among those 9 years of age.

Currently, Canadian children receive a combination vaccine of diphtheria and tetanus toxoids, acellular pertussis, inactivated poliomyelitis and Hemophilus influenzae type b (DTaP–IPV–Hib) at 2, 4, 6 and 18 months and a booster dose of DTaP–IPV between 4 and 6 years. Because of the recent upsurge in pertussis rates among adolescents, a booster dose of diphtheria–tetanus–acellular pertussis vaccine (dTap) has been offered to all Canadian adolescents since 2004.

Between 1989 and 2000, an average of 1113 (3.8 per 100 000) pertussis cases were admitted to hospital each year. The admission rate remained stable until 1995, when it began decreasing, reaching a low of 1.5 per 100 000 in 2000. Of cases admitted to hospital, 62% were under one year of age, for an average admission rate of 182.7 per 100 000 in this age group. Between 1991 and 2001, 89% of infants admitted to IMPACT hospitals (12 tertiary care pediatric hospitals across Canada) with pertussis were younger than 6 months of age. The ratio of reported cases to hospital separations increased from 1.1:1 in 1988 to 11.2:1 in 2000. The increase in this ratio is due in part to a shift in cases to older age groups and to the improved diagnosis and reporting of pertussis cases. The decrease in hospital admission rates in the last few years may be due in part to the greater efficacy of the acellular vaccine. However, infants who are not yet fully vaccinated remain at high risk of severe disease requiring hospital admission. Between 1989 and 2000, 19 pertussis-related deaths were reported. Of these, 16 (84.2%) were among infants, of whom all but one were younger than 3 months and of whom only one had been vaccinated.

The changing epidemiology of pertussis in Canada in the 1990s has led to the emergence of groups at higher risk of the disease: young infants, adolescents and adults. Cases admitted to hospital have shifted to infants younger than 6 months, and deaths are particularly high among infants younger than 3 months, who have few options for protection. Every effort should be made to vaccinate infants at the recommended age and to diagnose and treat pertussis in children and adults in contact with infants.

The recently implemented dTap immunization program for adolescents is expected to curb the increasing incidence in this age group. However, decreased circulation of Bordetella pertussis and waning immunity may lead to a continued increase in rates of pertussis among adults. To decrease the risk among adults and their contacts, the National Advisory Committee on Immunization recommends that all Canadian adults receive a single dose of dTap vaccine instead of a tetanus–diphtheria booster.

Footnotes

  • Competing interests: None declared.

REFERENCES

  1. 1.↵
    Gustafsson L, Hallander HO, Reizenstein E, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996;334:349-55.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Bentsi-Enchill AD, Halperin SA, Scott J, et al. Estimates of the effectiveness of a whole-cell pertussis vaccine from an outbreak in an immunized population. Vaccine 1997;15:301-6.
    OpenUrlCrossRefPubMed
  3. 3.↵
    McWha L, MacArthur A, Badiani T, et al. Measuring up: Results from the National Immunization Coverage Survey, 2002. Can Commun Dis Rep 2004;30:37-50.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 174 (4)
CMAJ
Vol. 174, Issue 4
14 Feb 2006
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Changing epidemiology and emerging risk groups for pertussis
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Changing epidemiology and emerging risk groups for pertussis
Eleni Galanis, Arlene S. King, Paul Varughese, Scott Alan Halperin
CMAJ Feb 2006, 174 (4) 451-452; DOI: 10.1503/cmaj.050379

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Changing epidemiology and emerging risk groups for pertussis
Eleni Galanis, Arlene S. King, Paul Varughese, Scott Alan Halperin
CMAJ Feb 2006, 174 (4) 451-452; DOI: 10.1503/cmaj.050379
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue
  • Dans ce numéro
  • PubMed
  • Google Scholar

Cited By...

  • Duration of Pertussis Immunity After DTaP Immunization: A Meta-analysis
  • Complete health checkup for adults: Update on the Preventive Care Checklist Form(C)
  • Has the change to acellular pertussis vaccine improved or worsened pertussis control?
  • Google Scholar

More in this TOC Section

  • Canada’s response to the initial 2 years of the COVID-19 pandemic: a comparison with peer countries
  • Excess mortality, COVID-19 and health care systems in Canada
  • Implementing social interventions in primary care
Show more Analysis

Similar Articles

Collections

  • Topics
    • Infectious diseases
    • Pediatrics
    • Vaccination

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire